singulair
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $3.34 | $100.33 (0%) | 🛒 Add to cart |
| 60 | $2.51 | $200.66 $150.50 (25%) | 🛒 Add to cart |
| 90 | $2.23 | $301.00 $200.66 (33%) | 🛒 Add to cart |
| 120 | $2.10 | $401.33 $251.83 (37%) | 🛒 Add to cart |
| 180 | $1.96 | $601.99 $352.17 (42%) | 🛒 Add to cart |
| 270 | $1.87
Best per pill | $902.99 $503.67 (44%) | 🛒 Add to cart |
| Product dosage: 4mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.40 | $42.14 (0%) | 🛒 Add to cart |
| 60 | $1.15 | $84.28 $69.23 (18%) | 🛒 Add to cart |
| 90 | $1.08 | $126.42 $97.32 (23%) | 🛒 Add to cart |
| 120 | $1.05 | $168.56 $125.42 (26%) | 🛒 Add to cart |
| 180 | $1.00 | $252.84 $180.60 (29%) | 🛒 Add to cart |
| 270 | $0.98 | $379.26 $263.87 (30%) | 🛒 Add to cart |
| 360 | $0.96
Best per pill | $505.67 $347.15 (31%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.37 | $71.24 (0%) | 🛒 Add to cart |
| 60 | $1.89 | $142.47 $113.38 (20%) | 🛒 Add to cart |
| 90 | $1.74 | $213.71 $156.52 (27%) | 🛒 Add to cart |
| 120 | $1.66 | $284.94 $198.66 (30%) | 🛒 Add to cart |
| 180 | $1.58 | $427.41 $283.94 (34%) | 🛒 Add to cart |
| 270 | $1.53
Best per pill | $641.12 $412.36 (36%) | 🛒 Add to cart |
Synonyms
| |||
Montelukast sodium, a selective leukotriene receptor antagonist, represents one of the most prescribed medications globally for managing asthma and allergic rhinitis. Marketed under the brand name Singulair, this once-daily oral tablet works by blocking inflammatory pathways distinct from corticosteroids, offering clinicians an important tool for step-up therapy in persistent asthma and seasonal allergy management. Its unique mechanism targeting cysteinyl leukotriene receptors makes it particularly valuable for patients with exercise-induced bronchoconstriction and aspirin-exacerbated respiratory disease.
1. Introduction: What is Singulair? Its Role in Modern Medicine
Singulair (montelukast sodium) is a prescription medication classified as a leukotriene receptor antagonist (LTRA). Approved by the FDA in 1998, it has become a cornerstone in the management of respiratory conditions, particularly asthma and allergic rhinitis. Unlike rescue inhalers that provide immediate symptom relief, Singulair works as a preventive controller medication, reducing underlying inflammation that causes airway constriction and allergic symptoms.
The significance of Singulair in modern therapeutics lies in its oral administration and unique anti-inflammatory pathway. While inhaled corticosteroids remain first-line for persistent asthma, Singulair offers an alternative for patients who cannot or will not use inhalers properly, particularly children and elderly patients. The medication’s once-daily dosing and lack of systemic steroid effects make it appealing for long-term management.
Clinical practice has revealed Singulair’s particular effectiveness in specific asthma phenotypes. We’ve consistently observed better responses in patients with allergic triggers, exercise-induced symptoms, and those with concomitant allergic rhinitis. This has led to its positioning as both monotherapy for mild persistent asthma and adjunctive therapy in more severe cases.
2. Key Components and Bioavailability of Singulair
The active pharmaceutical ingredient in Singulair is montelukast sodium, chemically described as [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid, monosodium salt. The molecular weight is 608.18, and it’s formulated as the sodium salt to enhance solubility and absorption.
Pharmaceutical Formulations:
- Chewable tablets: 4mg and 5mg strengths for pediatric use
- Oral tablets: 10mg for adults and adolescents
- Oral granules: 4mg packets for young children who cannot swallow tablets
Bioavailability studies demonstrate that montelukast reaches peak plasma concentrations within 3-4 hours after oral administration. The mean oral bioavailability is approximately 64%, with absorption not significantly affected by standard meals. The medication is highly protein-bound (>99%) and undergoes extensive hepatic metabolism via cytochrome P450 enzymes, primarily CYP3A4 and CYP2C9.
The elimination half-life ranges from 2.7 to 5.5 hours in healthy young adults, supporting the once-daily dosing regimen. Interestingly, we’ve noted some variation in clearance rates among different ethnic populations, though this rarely requires dosing adjustments in clinical practice.
3. Mechanism of Action: Scientific Substantiation
Singulair’s therapeutic effect stems from its highly selective antagonism of cysteinyl leukotriene type 1 (CysLT1) receptors. To understand this mechanism, we need to appreciate the leukotriene pathway in inflammatory responses.
When mast cells and eosinophils are activated by allergens or other triggers, they release arachidonic acid metabolites through the 5-lipoxygenase pathway. This produces cysteinyl leukotrienes (LTC4, LTD4, LTE4) - potent inflammatory mediators that cause bronchoconstriction, increased vascular permeability, mucus secretion, and eosinophil recruitment.
Montelukast competitively blocks CysLT1 receptors in human airway smooth muscle cells and other target tissues, preventing leukotrienes from binding and initiating the inflammatory cascade. Think of it as a specialized key that fits into the receptor lock but doesn’t turn it, while blocking the actual keys (leukotrienes) from entering.
The clinical implications are significant: by blocking this specific inflammatory pathway, Singulair reduces bronchoconstriction, decreases airway edema, and diminishes mucus production without affecting other inflammatory pathways like corticosteroids do. This explains why some patients respond dramatically to Singulair while others show minimal benefit - it depends on whether leukotrienes play a major role in their particular disease pathophysiology.
4. Indications for Use: What is Singulair Effective For?
Singulair for Asthma
Singulair is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months and older. It demonstrates particular efficacy in:
- Exercise-induced bronchoconstriction (taken at least 2 hours before exercise)
- Aspirin-exacerbated respiratory disease (AERD)
- Allergic asthma with identifiable triggers
- Patients who cannot tolerate inhaled corticosteroids
The reduction in asthma exacerbations ranges from 30-45% in various studies, with improved peak flow measurements and reduced rescue medication use.
Singulair for Allergic Rhinitis
For seasonal allergic rhinitis in patients aged 2 years and older, and perennial allergic rhinitis in patients aged 6 months and older, Singulair significantly improves nasal symptoms including congestion, rhinorrhea, sneezing, and itching. The effect size is comparable to second-generation antihistamines but through a different mechanism, making combination therapy particularly effective.
Off-label Applications
Clinical experience has revealed several valuable off-label uses:
- Chronic urticaria resistant to antihistamines
- Eosinophilic esophagitis as adjunctive therapy
- Viral-induced wheezing in children
- Mild obstructive sleep apnea related to allergic inflammation
5. Instructions for Use: Dosage and Course of Administration
Proper administration is crucial for Singulair’s effectiveness. The medication should be taken once daily in the evening for asthma, while allergic rhinitis dosing can be morning or evening based on symptom patterns.
| Indication | Age Group | Dosage | Administration |
|---|---|---|---|
| Asthma | 12-23 months | 4mg oral granules | Once daily in evening |
| Asthma | 2-5 years | 4mg chewable tablet | Once daily in evening |
| Asthma | 6-14 years | 5mg chewable tablet | Once daily in evening |
| Asthma | 15+ years | 10mg tablet | Once daily in evening |
| Allergic Rhinitis | 2-5 years | 4mg chewable tablet | Once daily any time |
| Allergic Rhinitis | 6-14 years | 5mg chewable tablet | Once daily any time |
| Allergic Rhinitis | 15+ years | 10mg tablet | Once daily any time |
| Exercise-induced asthma | 6+ years | Single dose 2+ hours before exercise | Do not take additional dose within 24 hours |
For asthma management, clinical response typically begins within the first day of administration, though maximum benefit may take 3-4 weeks. Patients should be advised that Singulair is not a rescue medication and will not treat acute asthma attacks.
6. Contraindications and Drug Interactions
Absolute Contraindications:
- Hypersensitivity to montelukast or any component of the formulation
- Patients with phenylketonuria (specific to chewable tablets containing aspartame)
Important Precautions: The FDA added a Boxed Warning in 2020 regarding neuropsychiatric events including agitation, depression, sleeping problems, and suicidal thoughts and actions. We must carefully assess patients for psychiatric history and monitor for behavioral changes.
Drug Interactions:
- Rifampin: Reduces montelukast AUC by 40%
- Phenobarbital: May decrease montelukast concentrations
- Gemfibrozil: Increases montelukast concentrations approximately 45%
Special Populations:
- Pregnancy: Category B - use only if clearly needed
- Lactation: Montelukast is excreted in breast milk - caution advised
- Hepatic impairment: Moderate to severe impairment may increase exposure
- Renal impairment: No dosage adjustment needed
7. Clinical Studies and Evidence Base
The evidence supporting Singulair’s efficacy spans decades of rigorous research. The initial pivotal trials published in the American Journal of Respiratory and Critical Care Medicine demonstrated significant improvements in FEV1, reduced daytime and nighttime symptoms, and decreased β-agonist use.
A landmark 2001 study in the New England Journal of Medicine compared montelukast with inhaled beclomethasone in chronic asthma, finding that while inhaled corticosteroids provided superior overall control, montelukast showed comparable efficacy in specific patient subgroups, particularly those with less severe disease and prominent allergic components.
More recent real-world evidence from the TENOR study (The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens) revealed that patients receiving leukotriene receptor antagonists like Singulair had significantly fewer asthma exacerbations and improved quality of life scores compared to those on short-acting bronchodilators alone.
The PRESEAL study specifically examined Singulair for exercise-induced bronchoconstriction in athletes, demonstrating 60% protection against EIB - a finding that has made it particularly valuable for competitive athletes who cannot use β-agonists due to sporting regulations.
8. Comparing Singulair with Similar Products
When considering leukotriene modifiers, clinicians choose between Singulair and zafirlukast (Accolate). The key differences:
| Parameter | Singulair (montelukast) | Zafirlukast (Accolate) |
|---|---|---|
| Dosing frequency | Once daily | Twice daily |
| Food interactions | None | Reduced absorption with food |
| Pediatric indication | ≥12 months | ≥5 years |
| Drug interactions | Minimal | Significant CYP450 interactions |
| Administration | Any time | 1 hour before/2 hours after meals |
Compared to inhaled corticosteroids, Singulair offers the advantage of oral administration and different mechanism, but generally provides less potent anti-inflammatory effects for moderate to severe asthma. The decision often comes down to patient phenotype, adherence considerations, and side effect profiles.
9. Frequently Asked Questions about Singulair
How long does it take for Singulair to work for allergies?
Most patients notice improvement in allergic rhinitis symptoms within the first day of treatment, with maximum benefit achieved within 3-5 days.
Can Singulair be stopped abruptly?
Yes, unlike corticosteroids, Singulair does not require tapering. However, asthma symptoms may return within days of discontinuation.
Is weight gain a side effect of Singulair?
No significant association with weight gain has been demonstrated in clinical trials or post-marketing surveillance.
Can Singulair be taken with antihistamines?
Yes, the combination is often used for enhanced allergic rhinitis control, as they work through complementary mechanisms.
Why is there a black box warning for Singulair?
The warning addresses rare but serious neuropsychiatric events reported in post-marketing surveillance, including agitation, depression, and suicidal ideation.
10. Conclusion: Validity of Singulair Use in Clinical Practice
Singulair remains a valuable therapeutic option nearly 25 years after its introduction, particularly for specific asthma phenotypes and as combination therapy for allergic conditions. The risk-benefit profile favors its use in appropriate patient populations with careful monitoring for neuropsychiatric effects.
The medication’s unique mechanism, oral administration, and favorable safety profile (excluding the neuropsychiatric concerns) ensure its continued role in respiratory therapeutics. As we better understand asthma endotypes and personalized medicine approaches, Singulair’s position may become even more targeted to patients with leukotriene-driven disease.
I remember when we first started using montelukast back in the early 2000s - we were skeptical about these newfangled “leukotriene modifiers.” The pharmaceutical reps kept throwing around biochemical pathways that half of us had forgotten since medical school. Dr. Henderson in our practice was adamant it was just expensive placebo, while I was more optimistic based on the early trial data.
The turning point for me was Sarah, a 16-year-old competitive swimmer with exercise-induced bronchospasm that was ruining her chances at college scholarships. She’d tried everything - albuterol made her jittery, inhaled corticosteroids affected her voice, cromolyn was impractical before meets. We started her on Singulair about 2 hours before practice, and within a week she was back in the pool without gasping for air after intervals. Her mother called me crying with relief - said it had given Sarah her life back. That case alone convinced several skeptics in our group.
Then there was Mr. Davison, 68, with severe COPD and recurrent exacerbations. We added Singulair mostly out of desperation after his third hospitalization that year. Surprisingly, his exacerbation frequency dropped from every 2-3 months to just once in the following year. Nothing in the literature at that time supported use in pure COPD, but it worked for him. We never figured out why - maybe he had an asthmatic component we’d missed, or maybe leukotrienes played a bigger role in his particular disease than typical.
The neuropsychiatric side effects caught many of us off guard. We’d been prescribing it for years without incident, then suddenly started seeing these case reports. I had one patient - young college student - who developed severe insomnia and anxiety after starting Singulair for seasonal allergies. We discontinued it and symptoms resolved within days. Made me realize we need to listen more carefully to patients’ non-respiratory complaints.
What’s interesting is how practice patterns have evolved. We used to throw Singulair at every mild asthmatic - now we’re much more selective. The patients with clear allergic triggers, the exercise-induced folks, the aspirin-sensitive patients - they’re the ones who really benefit. The rest? Maybe not so much.
Follow-up on those early patients has been revealing. Sarah, the swimmer, eventually outgrew her exercise-induced symptoms in her mid-20s and stopped the medication. Mr. Davison stayed on it until he passed away from unrelated causes at 79, with relatively stable lung function throughout. The college student with anxiety issues? We later discovered she had underlying bipolar disorder that the Singulair might have unmasked.
The real value I’ve seen over two decades isn’t in the clinical trials or the biochemical pathways - it’s in those individual patients where nothing else worked, and Singulair somehow made the difference. We’ve got to remember that behind all the mechanisms and meta-analyses are real people trying to breathe easier.